Aldeyra Stock Crashes 70% After FDA Rejection, Sparking Investor Lawsuits

Edgen Stock·Mar 22 2026, 20:07

Share to

Share to

Copy link

Key Takeaways

Aldeyra Therapeutics faces legal scrutiny after the U.S. Food and Drug Administration (FDA) rejected its key drug candidate, triggering a catastrophic stock price collapse and prompting investigations into whether the company misled investors.

FDA Rejection: The FDA issued a Complete Response Letter for Aldeyra's dry eye disease drug, reproxalap, citing a lack of substantial evidence of its effectiveness.
Market Collapse: On March 17, 2026, Aldeyra's stock (ALDX) plummeted 70.7%, closing at $1.24 per share after losing $2.99 in a single day.
Legal Fallout: Multiple investor rights law firms, including Rosen Law Firm and Pomerantz LLP, have since announced investigations into potential securities fraud claims on behalf of shareholders.

ALDX Stock Collapses 70.7% After FDA Rejects Key Drug

Aldeyra Therapeutics (NASDAQ: ALDX) saw its stock price disintegrate on March 17, 2026, after the U.S. Food and Drug Administration (FDA) rejected its New Drug Application (NDA) for reproxalap, a treatment candidate for dry eye disease. The company's shares plunged $2.99, or 70.7%, to close at $1.24. The rejection came in the form of a Complete Response Letter (CRL), a formal notice from the FDA that it cannot approve the application in its present form.

The FDA's letter stated there was a "lack of substantial evidence" that the drug was effective. Regulators noted that the "inconsistency of study results raises serious concerns about the reliability and meaningfulness of the positive findings" and concluded that the "totality of evidence from the completed clinical trials does not support the effectiveness of the product." This feedback effectively halts the drug's path to market and invalidates the clinical data investors had relied on.

Law Firms Investigate Aldeyra for Misleading Investors

In the days after the stock's collapse, multiple global investor rights law firms, including Rosen Law Firm and Pomerantz LLP, announced investigations into Aldeyra. The probes focus on whether the company and its executives issued materially misleading business information to the public regarding reproxalap's efficacy and prospects for approval. The goal of these investigations is to determine if grounds exist for a class-action lawsuit to recover shareholder losses.

A potential lawsuit would allege that Aldeyra's positive statements about its clinical trials were not supported by the underlying data, creating an artificially inflated stock price that led to significant investor damages when the FDA's negative assessment was revealed. The announcements, such as the one from Rosen Law Firm on March 22, 2026, call for shareholders who suffered losses to join a prospective class action.